Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment

Prof Monica Bocchia - University of Siena, Siena, Italy
Peripheral blood CD26 leukaemia stem cell monitoring in CML during TKI treatment ( Prof Monica Bocchia - University of Siena, Siena, Italy )
8 Dec 2020

Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective

Dr Shaji Kumar and Dr Wenming Chen
Continuous therapy in multiple myeloma; updates from MM4 and MM6 including China perspective ( Dr Shaji Kumar and Dr Wenming Chen )
8 Dec 2020

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation

Dr Jorge Cortes - Augusta University, Augusta, USA
First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )
8 Dec 2020

Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
8 Dec 2020

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data

Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia
Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )
8 Dec 2020

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil
Five year update of ECHELON-1 for classical Hodgkin lymphoma ( Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil )
8 Dec 2020

Blinatumomab and oral TKIs for the treatment of Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
Blinatumomab and oral TKIs for the treatment of Ph  ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )
8 Dec 2020

D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph ALL

Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA
D-ALBA update: Frontline sequential dasatinib and blinatumomab in adult Ph  ALL ( Dr Mark Geyer - Memorial Sloan Kettering Cancer Center, New York, USA )
8 Dec 2020

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina
Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )
8 Dec 2020

Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results

Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany
Bosutinib versus imatinib for newly diagnosed chronic phase CML: BFOREfinal 5-year results ( Prof Tim Brümmendorf - RWTH Aachen University, Aachen, Germany )
7 Dec 2020

Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients

Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain
Weekly carfilzomib and dexamethasone plus/minus cyclophosphamide for RRMM patients ( Dr Albert Oriol - Josep Carreras Leukaemia Research Institute, Badalona, Spain )
7 Dec 2020

Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
7 Dec 2020